MX378983B - Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. - Google Patents

Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Info

Publication number
MX378983B
MX378983B MX2017014300A MX2017014300A MX378983B MX 378983 B MX378983 B MX 378983B MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 378983 B MX378983 B MX 378983B
Authority
MX
Mexico
Prior art keywords
compositions
methods
histone deacetylase
deacetylase inhibitors
inhibitors
Prior art date
Application number
MX2017014300A
Other languages
English (en)
Spanish (es)
Other versions
MX2017014300A (es
Inventor
Alan F Haughan
de Poël Amanda Van
Andrew J Stott
Celia Dominguez
Christopher A Luckhurst
Elizabeth A Saville-Stones
Grant Wishart
Michael Wall
Michel C Maillard
Perla Breccia
Rebecca E Jarvis
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017014300A publication Critical patent/MX2017014300A/es
Publication of MX378983B publication Critical patent/MX378983B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MX2017014300A 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. MX378983B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017014300A MX2017014300A (es) 2018-08-09
MX378983B true MX378983B (es) 2025-03-10

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014300A MX378983B (es) 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Country Status (11)

Country Link
US (2) US10053434B2 (enExample)
EP (1) EP3291810B1 (enExample)
JP (1) JP6805172B2 (enExample)
KR (1) KR20180002729A (enExample)
CN (1) CN107735088B (enExample)
AU (1) AU2016258188B2 (enExample)
CA (1) CA2984618C (enExample)
EA (1) EA036965B1 (enExample)
IL (1) IL255448B2 (enExample)
MX (1) MX378983B (enExample)
WO (1) WO2016179554A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179554A1 (en) * 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291809B1 (en) 2015-05-07 2021-08-25 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3487843A1 (en) * 2016-07-22 2019-05-29 Syngenta Participations AG Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
WO2021021979A2 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
US20240327361A1 (en) * 2021-02-15 2024-10-03 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof
EP4504190A4 (en) 2022-04-08 2026-03-25 Eikonizo Therapeutics Inc OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005313108B2 (en) 2004-12-10 2011-05-26 Msd Italia S.R.L. Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
CN103764635B (zh) * 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
BR112014004741B1 (pt) * 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
EP2785713B1 (en) 2011-11-28 2016-09-07 Novartis AG Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US9822058B2 (en) * 2012-04-05 2017-11-21 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2016179554A1 (en) * 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291809B1 (en) 2015-05-07 2021-08-25 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos

Also Published As

Publication number Publication date
EP3291810A4 (en) 2018-11-07
AU2016258188A1 (en) 2017-11-23
CN107735088B (zh) 2021-11-02
IL255448A0 (en) 2017-12-31
WO2016179554A1 (en) 2016-11-10
US10053434B2 (en) 2018-08-21
IL255448B2 (en) 2023-07-01
IL255448B1 (en) 2023-03-01
HK1252487A1 (en) 2019-05-24
EA201792247A1 (ru) 2018-06-29
BR112017023711A2 (pt) 2018-07-17
US20190202795A1 (en) 2019-07-04
KR20180002729A (ko) 2018-01-08
EA036965B1 (ru) 2021-01-20
AU2016258188B2 (en) 2021-08-26
EP3291810A1 (en) 2018-03-14
CA2984618C (en) 2024-01-09
JP2018515489A (ja) 2018-06-14
JP6805172B2 (ja) 2020-12-23
EP3291810B1 (en) 2022-08-10
US20160326124A1 (en) 2016-11-10
CN107735088A (zh) 2018-02-23
MX2017014300A (es) 2018-08-09
CA2984618A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MX379817B (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX2017014300A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CO2018004124A2 (es) Compuestos heterocíclicos
DK3442973T3 (da) Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2019012434A (es) Agentes inductores de apoptosis.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
HUE057041T2 (hu) Hiszton deacetiláz hetero-halogén gátlói
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
EP3624804A4 (en) HISTONE DEACETYLASE INHIBITORS (HDAC)
HK1220407A1 (zh) 组蛋白去乙酰酶抑制剂,其组合物及其使用方法
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DK3653620T3 (da) Nye heteroarylamid-derivater som selektive inhibitorer af histondeacetylaser 1 og 2 (HDAC1-2)
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MX2017007377A (es) Compuestos organicos.
HK1220406A1 (zh) 组蛋白去乙酰酶抑制剂及组合物
EP3820859C0 (en) HISTONE DEACETYLASE INHIBITORS
DK3362450T3 (da) N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose